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Background
In a study of childhood acute lymphoblastic leukemia (CoALL 06-97 study), the in vitro sensi-
tivity of the patients’ cells to prednisolone, vincristine and asparaginase was introduced as a
new additional risk parameter for treatment stratification. In parallel in vivo treatment response
was assessed by determining the presence and extent of minimal residual disease in a subset of
patients (n=224). Here we report the long-term impact of in vitro sensitivity-based risk stratifi-
cation according to survival and compare the results of in vitro sensitivity with in vivo response.
Design and Methods
Patients with a sensitive in vitro profile were treated with a reduced intensity protocol (n=167)
whereas patients defined as low risk according to conventional parameters but with a resistant
in vitro profile were given intensified therapy (n=47).
Results
At a median follow-up of 6.8 years event-free survival was 0.80±0.03 for patients with a sensi-
tive profile, 0.73±0.03 for those with an intermediate profile and 0.67±0.08 for those with a
resistant profile  (P=0.015). Overall, the treatment results of the cases stratified according to in
vitro sensitivity were similar to those of the historical control group stratified based on conven-
tional risk factors. Minimal residual disease at the end of induction was a strong predictor of
outcome in B-precursor and T-cell acute lymphoblastic leukemia. There was no correlation
between in vitro and in vivo treatment response in B-precursor leukemia (Spearman’s r=0.13;
P=0.15) in contrast to T-cell acute lymphoblastic leukemia (Spearman’s r=0.63; P<0.001)
Conclusions
A moderate reduction in treatment intensity for patients with a sensitive in vitro profile was
possible without jeopardizing treatment outcome. However, in vitro drug testing was affected
by a decrease in risk predictive power over time and was not correlated with in vivo assessment
of minimal residual disease in B-precursor acute lymphoblastic leukemia. It was, therefore,
abandoned in favor of the assessment of in vivo response in subsequent CoALL trials.
Key words: acute lymphoblastic leukemia, in vitro drug testing, risk-adapted treatment, childhood,
minimal residual disease.
Citation: Escherich G, Tröger A, Göbel U, Graubner U, Pekrun A, Jorch N, Kaspers G,
Zimmermann M, zur Stadt U, Kazemier K, Pieters R, Den Boer ML, Horstmann M, and Janka
GE.The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in
acute lymphoblastic leukemia of childhood (CoALL 06-97). Haematologica 2011;96(6):854-862.
doi:10.3324/haematol.2010.039735
©2011 Ferrata Storti Foundation. This is an open-access paper. 
The long-term impact of in vitro drug sensitivity on risk stratification and 
treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97)
Gabriele Escherich,1* Anja Tröger,3* Ulrich Göbel,3 Ulrike Graubner,4 Arnulf Pekrun,5 Norbert Jorch,6 Gjl Kaspers,7
Martin Zimmermann,8 Udo zur Stadt,²  Karin Kazemier,9 Rob Pieters,9 Monique L. Den Boer,9 Martin Horstmann,1,2
and Gritta E. Janka1 on behalf of the CoALL study group, Hamburg, Germany
1University Medical Center Eppendorf, Department of Pediatric  Hematology/Oncology, Hamburg, Germany; ²Children’s Cancer
Research Institute, Hamburg, Germany; 3Clinic for Pediatric Hematology/Oncology, Heinrich Heine University of Düsseldorf,
Germany; 4Department of Pediatric Hematology/Oncology, Dr. v. Haunersches Kinderspital, Munich, Germany; 5Prof. Hess
Children’s Hospital, Bremen, Germany; 6Gilead Children’s Hospital, Bielefeld, Germany; 7Department VU University Medical Center,
Amsterdam, The Netherlands; 8Department of Pediatric Hematology/Oncology, Medical School, Hannover, Germany; and
9Department of Pediatric Oncology and Hematology, Erasmus MC/Sophia Children’s Hospital Rotterdam, The Netherlands 
ABSTRACT
854 haematologica | 2011; 96(6)
Introduction
Traditionally, antileukemic therapy has been adjusted
on the basis of risk factors such as age, white blood cell
count, immunological phenotype, specific chromosomal
alterations and response to therapy. In vitro1-4 and in vivo5-8
drug resistance testing, e.g. by a colorimetric-based 3-[4.5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide
(MTT) assay or a fluorescence-based fluorometric micro-
culture cytotoxicity assay, was established with the aim of
strengthening the power of risk prediction in childhood
acute lymphoblastic leukemia (ALL).
Several groups have studied the prognostic value of drug
resistance in children with newly diagnosed ALL.
Resistance to single agents such as glucocorticoids, vinca
alkaloids, L-asparaginase and anthracyclines was shown
to be associated with unfavorable immunophenotypic and
cytogenetic subtypes of ALL as well as an older age of
patients.9,10 Furthermore, resistance of leukemic cells to
single agents predicted unfavorable short-term (induction
failure) and long-term (relapse) clinical outcome.1,11-13
A drug resistance profile, combining resistance data on
three drugs, was shown to predict clinical outcome better
than resistance to single agents.3,11,13,14 A profile combining
in vitro cellular resistance to prednisolone, vincristine and
L-asparaginase (PVA) was most discriminative for clinical
outcome. In Japanese, Polish and Dutch studies, patients
with a resistant profile suffered from induction failure or
relapse more often than did patients with an intermediate
or sensitive profile. In multivariate analyses, the predictive
value of the drug resistance profile remained highly signif-
icant suggesting a potential use as a prognostic factor for
newly diagnosed ALL of childhood.3,12,14
The value of a drug resistance profile as a risk predictor
was confirmed in a German cohort of patients treated
according to the CoALL 05-92 protocol. In this study, the
MTT assay was used to determine the patients’ in vitro
responsiveness towards PVA. A risk was assigned in 202
cases and very low-risk and a high-risk groups were iden-
tified using previously determined criteria for resist-
ance.15,16
Consequently, in vitro resistance to drugs was used in the
CoALL 06-97 study as an additional risk parameter for
treatment stratification, allocating patients with a very
sensitive profile to reduced therapy and patients with a
resistant profile to more intensive treatment.
The PVA score as well as age, initial white blood cell
(WBC) count and immunophenotype have the advantage
that they are obtained upfront at diagnosis and therefore
allow for early adjustment of therapy. However, over the
past years it became increasingly clear that in the interplay
between host and leukemia, not only biological character-
istics of the malignant cells but also host factors might crit-
ically influence treatment response and outcome.
Techniques with sufficient sensitivity and specificity to
detect submicroscopic levels of leukemic cells (minimal
residual disease, MRD) have been developed. Several
studies showed that regular assessment of MRD by poly-
merase chain reaction (PCR) analysis or flow cytometry
does indeed facilitate the identification of patients with a
high or low risk of relapse.5-7,17,18 While both MRD and the
PVA score have been used for treatment stratification in
different clinical trials, there are only two small retrospec-
tive19,20 and one prospective study21 investigating a poten-
tial relationship between MRD and in vitro chemoresis-
tance. They revealed a weak correlation between MRD
and response to single drugs such as prednisolone and
doxorubicin.21 Here we describe the relevance of the in
vitro response to treatment (evaluated by the PVA score)
and the in vivo response (assessed by the presence and
degree of MRD) for predicting outcome in a large cohort
of 224 children uniformly treated according to the CoALL
06-97 protocol. 
Design and Methods
Assessment of the PVA score 
At diagnosis leukemia samples from bone marrow and/or
peripheral blood were tested for in vitro cytotoxicity based on the
MTT assay which has been described elsewhere in detail.16
Briefly, leukemic cells were incubated in the absence (control) or
presence of six different concentrations of drugs in duplicate
(prednisolone: range, 0.06 to 250 mg/mL; vincristine: range, 0.05
to 50 µg/mL; asparaginase: range, 0.003 to 10 IU/mL). After 4
days of culture at 37ºC in humidified air containing 5% CO2,
0.45 mg/mL of MTT were added. Formazan crystals, produced
by viable cells only, were dissolved in acidified isopropanol and
quantified by spectrophotometry at 562 nm. The in vitro cytotox-
icity of prednisolone, vincristine and L-asparaginase was deter-
mined. For each patient a three-drug resistance profile was gen-
erated that combined the results of the individually tested drugs
into one score, i.e. the PVA score, as described previously.16 In
brief, marked sensitivity towards a drug was scored as 1, inter-
mediate sensitivity was scored as 2 and resistance was scored as
3. Combining the separate scores for prednisolone, vincristine
and L-asparaginase of each patient resulted in an individual PVA
score that varied between 3 (sensitive to all three drugs) and 9
(resistant to all three drugs). 
Analysis of minimal residual disease 
For MRD analysis, DNA was isolated from bone marrow
mononuclear cells obtained at diagnosis, day 15 of the induction
phase, at the end of induction (day 29) and at week 12 for low-
risk patients and at week 15 for high-risk patients.  
PCR studies for MRD analysis were performed with
immunogloblulin heavy chain (IGH) and T-cell receptor (TCR)
gene rearrangements as targets. DNA samples from diagnosis
were screened for clonal products using the BIOMED-2 primers
for the Igk deleting element (Kde), complete and incomplete
TCRδ, TCRγ and TCRb gene rearrangements. IGH rearrange-
ments were identified using seven VH region and one JH consen-
sus primer. Products were analyzed for clonality on 6% acry-
lamide gels and positive products were further processed.
Junctional regions of clonal products were sequenced directly
and patient-specific junctional regions were identified for gener-
ation of allele-specific PCR primers. Biclonal or biallelic products
were cloned using the TOPO-TA cloning kit (Invitrogen) and
then processed adequately for generation of suitable patient-spe-
cific primers. Subsequently PCR-MRD targets were tested for
specificity and sensitivity to reach a sensitivity and a quantifi-
able range of 1¥10-4 for at least two targets. Real-time quantita-
tive PCR was performed and interpreted according to the guide-
lines developed within the European Study Group for MRD
detection in ALL (ESG-MRD ALL).22 In detail, sequence-specific
TaqMan probes were used on a LC480 machine (Roche). Ten-
fold serial dilutions of diagnostic DNA were prepared in pooled
peripheral blood DNA extracted from at least five healthy
donors. Quantification was performed using this standard curve
and triplicate follow-up samples including 500 ng DNA in each
reaction.
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Patients
Between August 4, 1997 and June 30, 2003 752 patients younger
than 18 years with newly diagnosed ALL from 18 cooperating cen-
ters in Germany were registered in the CoALL 06-97 study.
Eighty-five patients were excluded: 19 patients because they were
younger than 1 year at diagnosis and were treated according to the
international Interfant study, 36 patients because they had non-
Hodgkin’s lymphoma and were not stratified according to the
results of in vitro cytotoxicity testing and 30 patients not eligible for
this study because of pre-treatment (n=14), other treatment fol-
lowing the parents’ or physicians’ decision (n=8), ALL being a sec-
ond malignancy (n=5), or an additional major medical condition
preventing therapy according to the protocol (n=3). Thus 667
patients were eligible and evaluable for the study. The study was
approved by competent authorities and ethics committees.
Written informed consent was obtained from all parents or
guardians.
A first risk stratification comprised the traditional risk criteria:
age, WBC count, immunophenotype, response to induction and
chromosomal rearrangements. Patients older than 10 years, with
T-lineage or pro-B ALL, an initial WBC of 25¥109/L or more, no
remission at day 29 after induction therapy, or translocation 4;11
or 9;22 were considered at high risk. All other patients were allo-
cated to the low-risk group. After achieving remission a second
stratification was performed according to the results of the in vitro
drug resistance testing (Figure 1).
A PVA score of 8 or 9 in the high-risk group constituted an indi-
cation for stem cell transplantation provided that a matched sib-
ling donor was available. Patients in whom the score could not be
determined were allocated to low-risk or high-risk therapy on the
basis of traditional risk criteria. The characteristics of the patients
are summarized in Online Supplementary Table S1.
Treatment
The complete treatment is outlined in Online Supplementary
Table S2. Apart from treatment modifications according to the sec-
ond stratification based on the PVA score there were no other dif-
ferences between the CoALL 92 and CoALL 97 therapy. All
patients received the same prephase treatment with daunorubicin
and one dose of intrathecal methotrexate. During induction, vin-
cristine and daunorubicin were given weekly and methylpred-
nisolone was given daily. 
Low-risk patients
All low-risk patients received identical consolidation therapy,
followed by 6-mercaptopurine daily for 4 weeks and four doses of
intrathecal methotrexate (central nervous system phase). In rein-
duction for ‘low-risk reduced’ patients the doses of adriamycin
and dexamethasone were halved (Figure 2). Thus ‘low-risk
reduced’ patients received only one dose of adriamycin and 7 days
of dexamethasone, whereas ‘low-risk standard’ patients received
two doses of adriamycin and 14 days of dexamethasone. All low-
risk patients received the second part of reinduction (Figure 2).
High-risk and ‘low-risk intensified’ patients
‘Low-risk intensified’ and ‘high-risk standard’ patients received
the same treatment. All patients were given identical consolida-
tion therapy, followed by daily 6-mercaptopurine for 4 weeks and
four doses of intrathecal methotrexate. Patients with central nerv-
ous system involvement at diagnosis received cranial irradiation
(18 Gy), patients with T-ALL and patients with B-precursor ALL
and an initial WBC of 100¥109/L or more at diagnosis received pro-
phylactic cranial irradiation (12 Gy). Since 2001 irradiation has
been omitted for patients with B-precursor ALL and an initial
WBC count between 100¥109/L and 200¥109/L, if they have less
than 1¥109/L blasts in the peripheral blood 7 days after the first
dose of daunorubicin. In analogy to the management of ‘low-risk
reduced’ patients with a PVA score of 3 or 4, doses of adriamycin
and dexamethasone were halved for the ‘high-risk reduced’
patients during reinduction (Figure 2). As a consequence, ‘high-risk
reduced’ patients received two doses of adriamycin and 14 days of
dexamethasone, whereas ‘high-risk standard’ and ‘low-risk inten-
sified’ patients received four doses of adriamycin and 28 days of
dexamethasone. All high-risk patients received the second part of
reinduction. In February 2003, analysis of the patients in the high-
risk group as a whole showed that these patients had an inferior
outcome compared to that of patients in the CoALL 05-92 study.
During the remaining study period, 12 high-risk patients with a
PVA score of 3 or 4 were, therefore, treated with ‘high-risk stan-
dard’ therapy. Patients who failed to achieve remission by day 29,
or those with a t(4;11) or t(9;22) translocation were eligible for
stem cell transplantation in first remission. No treatment interven-
Table 1. Events according to in vitro drug sensitivity-based risk stratification in
all patients treated on protocol CoALL 06-97.
Low risk High risk
LR-R LR-S LR-I HR-R HR-S*
Number of patients n=93 n=183 n=47 n=74 n=270
Death in induction 1 1 3
Remission failure 3
(no remission achieved until day 56)
Death in remission 1 3 2 5
Death after SCT in first complete remission 6
Relapses 11 30 8 17 66
Bone marrow 7 22 6 9 46
Central nervous system 1 2 - 3 8
Testes - 1 1 1 3
Lymph nodes 1 1 - 1 -
BM and CNS 1 1 - 3 6
BM and testes - 3 1 - 3
CNS and testes 1 - - - -
Second malignancies 2 4
In CCR 81 ( 87%) 149 (81%) 37 (79%) 54 (73%) 183 (67%)
SCT: stem cell transplantation, BM: bone marrow; CNS: central nervous system; CCR: continuos
complete remission; LR-R: low risk reduced;  LR-S: low risk standard, LR-I: low risk intensified, HR-
R: high risk reduced; HR-S: high risk standard, *12 high-risk patients with a PVA score of 3 or 4
who were treated according to the HR-S protocol are included.
Figure 1. Stratification in CoALL 06-97 study according to WBC
count, age, immunophenotype and PVA score.
COALL-06-97
WBC < 25x109/L
C/ pre-B ALL
Age 1-10 years
Stratification 1
Stratification 2
PVA score
3+4
PVA score
5+6
PVA score
7-9
PVA score
5-9
PVA score
3+4
High risk
standard
High risk
reduced
Low risk
standard
Low risk
intensified
Low risk
reduced
High risk
score 8+9HSCT
No remission on day 29
t(9;22) or t(4;11)
Low risk High risk
WBC ≥25x109/L
ProB/T-ALL
Age≥10 years
t(9;22) t(4;11)
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tion was made according to the result of MRD assessment.
Maintenance therapy, consisting of daily 6-mercatopurine and
weekly methotrexate per os, was administered until 104 weeks
after diagnosis. Three, 6 and 9 months after the start of mainte-
nance therapy all patients who were not given central nervous sys-
tem irradiation received two doses of intrathecal methotrexate.
Statistical analysis
Each year patients’ data were collected in protocol-specific
forms and reviewed before data entry by the trial data monitoring
board, which also performed the statistical analysis. Probability of
event-free survival (pEFS) was estimated according to Kaplan and
Meier and compared between subgroups using the log-rank test.23
Event-free survival was defined as the time from diagnosis to the
first outcome event, which was failure to achieve remission (no
remission until day 56), death during induction, relapse, death
from any cause in remission or a second malignancy. Disease-free
survival was defined as the time from complete remission to first
relapse. The cumulative incidence of relapse was calculated by the
method of Kalbfleisch and Prentice and compared using Gray’s
test.24 Survival estimates are given as 10-year estimates with stan-
dard error (SE). Cox regression analysis was used for multivariate
analysis of pEFS.25 The models for multiple analyses included age
(cut-off 10 years), WBC (cut-off 25¥109/L), immunophenotype
(pro-B-ALL and T-ALL versus common/pre-B-ALL), and the addi-
tional high-risk criteria grouped into one covariate (other high-risk
criteria i.e. induction failure – no remission at day 29- or presence
of the chromosomal translocation t(9;22) or an MLL rearrange-
ment), level of MRD at the end of induction and the drug resist-
ance profile based on the PVA score as covariates. The χ2 test,
Fischer’s exact test and Spearman’s rank correlation analyses were
applied to compare the distribution of parameters between sub-
groups and correlation between parameters.
Results
Overall treatment results
The pEFS at 6 years and 10 years of follow-up for all 667
patients was 0.77±0.02 and 0.75 ±0.02, respectively. The
median follow-up of patients at risk was 6.8 years (range,
5.1–11.0 years). Between LR and HR patients the progno-
sis of low-risk and high-risk patients differed significantly
(10-year pEFS 0.81±0.02 versus 0.67±0.03; P=0.001) as did
the incidence of relapse (0.16±0.02 versus 0.25±0.03;
P=0.001). 
There were no significant differences in outcome and
incidence of relapse between patients with or without a
measurable PVA score (10-year pEFS 0.73±0.02 versus
0.76±0.03; P=0.985).
Five of 667 children (0.75%) died during induction ther-
apy and nine patients (1.3%; 3 low-risk and 6 high-risk
patients) died on therapy in remission due to infectious
complications. Thirty-seven patients underwent stem cell
transplantation, 12 of whom received a graft from a
matched related donor and 25 of whom were transplanted
from a matched unrelated donor. Only one high-risk
patient received a stem cell transplant based on a PVA
score of 8 without other criteria qualifying for transplanta-
tion. Six high-risk patients died after stem cell transplanta-
tion in first remission due to therapy-related complica-
tions and two patients died several years after completion
of therapy due to accidents. Thirty-six patients were not
in remission on day 29 but had achieved remission by day
56. All these patients were treated according to the ‘high-
risk standard’ protocol. Remission failure, defined as no
remission on day 56, was only seen in three high-risk
patients. Six patients developed a second malignancy. The
distribution of events is presented in Table 1.
Risk stratification by in vitro drug testing 
haematologica | 2011; 96(6) 857
Table 2. Distribution of PVA scores according to immunophenotype in CoALL 06-97 high-risk patients.
                                                       All patients                Low-risk patients High-risk patients
PVA Score                                          n=667                           n = 323
                                                                                                     All HR patients B - Precursor T - ALL
                                                                                                     n=344 HR patients n=250 HR patients n=94
3+4                                                           179 (35.1%)                         93 (36.6%) 86 (33.7%) 57 (29.6%) 29 (45.3%)
5+6                                                           226 (44.3%)                        114 (44.9%) 112 (43.5%) 96 (50.0%) 16 (25.0%)
7-9                                                            105 (20.6%)                         47 (18.5%) 58 (22.6%) 37 (19.3%) 19 (29.7%)
8+9                                                             41 (8.0%)                            16 (6.3%) 25 (9.8%) 13 (6.7%) 12 (18.7%)
∑ score                                                  510 (76.5%)                        254 (78.6%) 256 (74.6%) 192 (76.8%) 64 (68.1%)
n.d. score                                              157 * (22.5%)                     69 ** (21.4%) 88 ***(25.4%) 58 (23.2%) 30 (31.9%)
∑ sum; n.d. not determined; *MTT assay with no result: n=30; blasts did not survive the MTT test: n=70; too few blasts: n=27; MTT assay not performed due to pre-treatment or lack
of initial material: n=30 **MTT assay with no result: n=13; blasts did not survive the MTT test: n=31; too few blasts: n=16; MTT assay not performed due to pre-treatment or lack of
initial material: n=9 ***MTT assay with no result: n=17; blasts did not survive the MTT test: n=39; too few blasts: n=11; MTT assay not performed due to pre-treatment or lack of
initial material: n=21. 
Figure 2. Treatment in reinduction for low- and high-risk patients
depending on PVA stratification according to PVA score.
Reduction of therapy in reinduction
High-risk protocol
Low-risk protocol
Encircled parts of therapy were omitted in the reduced treatment arm
week 0 1 2
Vincristine 1.5 mg/m2
Adriamycin 30 mg/m2
PEG-Asparaginase 2500 IE/m2
Methotrexale (intrathecal)
Dexamethasone 10 mg/m2/day
Vincristine 1.5 mg/m2
Adriamycin 30 mg/m2
PEG-Asparaginase 2500 IE/m2
Methotrexale (intrathecal)
Dexamethasone 10 mg/m2/day
week 0 1 2 3 4 5
Success rate and distribution of the PVA scores
The PVA score could be determined in 510 of 667
patients (Table 2). The main reasons for failure to be able
to assign a score were a low fraction of blasts in the bone
marrow or peripheral blood and blasts not surviving 4
days of culture. The proportions of low-risk and high-risk
patients in whom the score could be determined were
similar. Patients for whom a PVA score could be deter-
mined did not differ from patients without a score with
respect to gender, age, initial WBC count and immunophe-
notype (data not shown). The distributions of the scores
between low-risk and high-risk patient with B-precursor
ALL were similar (χ2 P=0.33). There was a significant dif-
ference in score distribution between patients with B-pre-
cursor ALL and T-ALL high-risk patients (P=0.0004). T-
ALL patients presented more frequently with the very
ends of the PVA score, i.e. a score of 3 or 4 was found in
45.3% of T-ALL patients compared to in 29.6% of patients
with B-precursor ALL whereas a score of 8 or 9 was found
in 18.7%  of T-ALL patients and in 6.7% of B-precursor
ALL patients (Table 2). There was a significant trend to
higher PVA scores in patients who failed to achieve remis-
sion at the end of induction than in patients in remission
on day 29 (χ2 P=0.0001). Fourteen of the 39 patients (35%)
in whom induction failed had a PVA score of 7 or more
compared to 15% within the whole group and only four
out of 39 patients (10%) had a PVA score of 3 or 4 com-
pared to 25% of the patients in the entire group.  
Treatment outcome of patients stratified by PVA profile
Figure 3 shows the 10-year pEFS of patients with a sen-
sitive PVA profile (score 3 or 4; pEFS 0.80±0.03), an inter-
mediate PVA profile (score 5 or 6, pEFS 0.73±0.03) and a
resistant PVA profile (score 7, 8 or 9; pEFS 0.67±0.05). The
difference between patients with a PVA score of 3 or 4 and
that of patients with a score of 7, 8 or 9 is statistically sig-
nificant (P=0.015). This is mainly due to the worse prog-
nosis of high-risk patients with a score of 7-9 (pEFS
0.57±0.07). In contrast, the prognosis of low-risk patients
with a score of 7-9 who received intensified treatment
(pEFS 0.79±0.06) was similar to that of low-risk patients
with a score of 3 or 4 (pEFS 0.87±0.04) or a score of 5 or 6
(pEFS0.80±0.03). High-risk patients with a favorable score
(3 or 4) had a significantly better outcome than patients
with higher scores (7-9) (pEFS: 0.71±0.05 versus 0.57±0.07,
respectively; P=0.05). 
In vitro sensitivity testing and outcome in CoALL 05-92
compared to CoALL 06-97 
Two-hundred and two patients from the CoALL 05-92
study and 510 from the CoALL 06-97 study with an
informative PVA score were available for a comparative
analysis.
The overall outcome in both studies, which had an iden-
tical treatment backbone, was similar with a 10-year pEFS
of 0.75±0.02 in CoALL 06-97 versus 0.76±0.03 in CoALL
05-92 (P=0.95). Analyses of subgroups with different PVA
scores (3+4, 5+6 and 7-9) showed no statistically signifi-
cant differences in the pEFS between the two studies,
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858 haematologica | 2011; 96(6)
Figure 3. Ten-year probability of event-free survival in CoALL 06-97
patients according to PVA score; 167 patients with PVA score 3 or
4 versus 226 patients with PVA score 5 or 6 versus 105 patients
with PVA score 7-9 (in light gray 41 patients with PVA score 8 or 9)
(log-rank test for patients with score 3+4 versus 8+9 P=0.01)
Figure 4. Ten-year probability of event-free survival in CoALL 06-97
patients according to asparaginase (ASP) score (log-rank test: PVA
score 1 versus 2 P=0.0037, score 1 versus 3 P=0.0001).
Table 3A. Cox regression analysis of event-free survival.
Relative Lower Upper Significance
risk limit* limit* (P)
Asparaginase (=1) 0.47 0.32 0.68 <0.001
Immunophenotype 1.33 0.81 2.18 0.26
(T-ALL)
WBC (≥ 25¥109/L) 1.59 1.08 2.34 0.02
Age (≥ 10 years) 1.34 0.89 2.02 0.16
Induction failure/ 2.33 1.37 3.95 0.002
BCR-ABL/ MLL-AF4
Table 3B. Cox regression analysis of event-free survival including
MRD.**
Relative Lower Upper Significance
risk limit* limit* (P)
Asparaginase (=1) 0.60 0.30 1.19 0.14
Immunophenotype 1.44 0.64 3.23 0.38
(T-ALL)
WBC (≥ 25¥109/L) 1.07 0.50 2.28 0.85
Age (≥ 10 years) 0.75 0.33 1.68 0.48
MRD day 29 negative 0.38 0.18 0.83 0.01
*lower/upper limit of 95% confidence interval; **no patient with induction
failure/BCR-ABL/ MLL-AF4 among the patients with a MRD result.
1.0
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0.7
0.6
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0.2
0.1
0.0
1.0
0.9
0.8
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Log-Rank PVA 3-4 versus 7-9 P=0.015
Log-Rank  score 1 versus 2 P: 0.0037;
score 1 versus 3 P: <0.0001
Score 3+4 0.80 SE=0.03 (N=167, 31 events)
Score 5+6 0.73 SE=0.03 (N=226, 56 events)
Score 7-9 0.67 SE=0.05 (N=105, 34 events)
Score 8+9 0.62 SE=0.08 (N=41, 15 events)
ASP Score 1 0.82, SE=0.03 (N=239, 39 events)
ASP Score 2 0.71, SE=0.04 (N=151, 42 events)
ASP Score 3 0.64, SE=0.05 (N=117, 40 events)
years
years
0 1 2 3 4 5 6 7 8 9 10 11
0 1 2 3 4 5 6 7 8 9 10
P^
P^
either for low-risk and high-risk patients combined or in
separate analyses (Online Supplementary Table S3). Notably
167 patients (32%) with a score of 3 or 4 and reduced ther-
apy in the CoALL 06-97 study fared equally well as 39
patients with a score of 3 or 4 without therapy reduction
in the CoALL 95-92 study (pEFS 0.79 ±0.03 versus
0.81±0.06; P=0.81).Therapy intensification for 47 low-risk
patients with a resistant PVA profile (score 7-9) resulted in
a 10-year pEFS of 0.79 (SE=0.06) compared to 0.75
(SE=0.12) for 12 patients in the CoALL 05-02 study with a
resistant profile (P=0.76). 
Predictive value of resistance to L-asparaginase 
We also looked at the prognostic value of sensitivity to
each single drug. The individual scores for asparaginase
and prednisolone but not for vincristine were of prognos-
tic value. The overall population of patients, as well as
low-risk and high-risk patients separately, had a signifi-
cantly better outcome with a sensitive score of 1 for
asparaginase compared to patients with an asparaginase
score of 2 or 3 (P= 0.0037 for score 1 versus 2, P<0.0001 for
score 1 versus 3) (Figure 4). With regard to the pharmaco-
logical sensitivity towards prednisolone a score of 1 was
associated with a higher pEFS than the pEFS in patients
with a resistant score of 3 (P=0.0498 for score 1 versus 3)
whereas score 2 did not discriminate between the groups
(Online Supplementary Figure S1A,B)
Assessment of minimal residual disease
PCR-based measurements of MRD were undertaken
during the study period to evaluate whether the in vitro
sensitivity towards the three selected drugs was also
reflected by the in vivo response to induction therapy.
MRD was assessed in 224 patients (68/94 (72%) with T-
ALL and 156/573 (27%) with B-precursor ALL. The subset
of patients with B-precursor ALL in whom MRD was
measured did not differ from the whole cohort with
respect to gender, age, initial WBC count or chromosomal
translocation.
Prognostic value of minimal residual disease  
MRD at the end of induction was a strong predictor of
outcome. Among the 153 with B-precursor ALL, 59 (39%)
were MRD-negative at day 29 with an incidence of relapse
of 0.09 (SE=0.04), whereas the risk of relapse in patients
with a MRD load of 10-3 or more (39/153, 25%) was sig-
nificantly higher at 0.33 (SE=0.08) (P=0.002). Patients who
had a detectable MRD load of less than 10-3 had a relapse
rate of 0.24 (SE=0.06) (Figure 5A). Among the patients
with T–ALL no difference in outcome was seen between
patients with a negative or low MRD load (<10-3) at day
29. However, patients with a high MRD load (≥10-3) on
day 29 had a significantly worse outcome than that of
patients with a MRD load less than 10-3 on day 29 (relapse
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Figure 5. Incidence of relapse in CoALL 06-97 patients with MRD
measurement (A) Incidence of relapse according to MRD level at the
end of induction in patients with B-precursor ALL. (B) Incidence of
relapse according to MRD level at the end of induction in T–ALL
patients.
Figure 6. Correlation of MRD level at the end of induction and PVA
score. (A) Correlation of MRD level at the end of induction and PVA
score in T–ALL patients. (B) Correlation of MRD level at the end of
induction and PVA score in patients with B-precursor ALL.
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incidence 0.41, SE=0.08 versus 0.18, SE=0.07; P=0.02)
(Figure 5B).
After consolidation treatment (at week 12 in the low-
risk arm and week 15 in the high-risk arm), a sustained
positive MRD signal was detected predominantly in T-
ALL patients. Twelve of 46 T–ALL patients, in whom
MRD was assessed at this time point, had a MRD level
greater than 10-4. Among these 12 patients with a MRD
signal greater than 10-4 at this late time point, five suffered
from relapsing disease. Nine of 63 patients with B-precur-
sor ALL showed a positive MRD signal, three of whom
had a relapse. 
Correlation between in vitro PVA score and in vivo
assessment of minimal residual disease 
No association was found between PVA score and MRD
level at day 15 or 29 in patients with B-precursor ALL
(Spearman’s correlation coefficient day 15: r=0.13, P=0.17;
day 29: r=0.13, P=0.15) in contrast to T-ALL patients (cor-
relation coefficient day 15: r=0.57, P<0.0001; day 29:
r=0.63, P<0.0001) (Figure 6A,B). When comparing the in
vitro sensitivity towards the single drugs with induction
MRD levels, a strong correlation was found between
MRD levels on days 15 and 29 and asparaginase score only
in  T-ALL patients (χ2 0.00004). 
Multivariate analyses
When a Cox regression analysis of event-free survival
was applied taking into account the PVA score and tradi-
tional risk factors, it was found that initial WBC count and
high-risk features, such as induction failure and adverse
chromosomal translocations, had prognostic significance.
A PVA score of 3 or 4 was of borderline significance
(P=0.05). The Cox regression analysis of the scores for sin-
gle agents showed a strong prognostic power for the
asparaginase score (P=0.0001); initial WBC count and
high-risk features retained statistical significance. When
integrating MRD in this model only low MRD levels at the
end of induction (day 29) remained significant (P=0.01)
(Table 3A,B).
Discussion
Since the introduction of the first antileukemic agent by
Sidney Farber in 1948,27 cure rates for childhood ALL have
increased steadily.28-32 However, the intensity of treatment
protocols has reached a high level, and there has been con-
cern that a substantial proportion of patients is being
overtreated due to the lack of a refined risk assignment
which relies on traditional risk factors such as initial white
blood count, age, immunophenotype and chromosomal
translocations. In 1991 the group of Pieters et al.1 demon-
strated the prognostic value of an in vitro assay testing the
sensitivity of leukemic cells to drugs. Subsequent reports
from this group2-4 and others11-13 confirmed that a simple
and inexpensive assay is useful for allocating patients to
different risk categories. The CoALL 05-92 study prospec-
tively evaluated the value of the MTT assay in a cohort of
202 patients; after 5 years the probability of disease-free
survival for patients with a PVA score of 3 or 4 was
0.93±0.05 versus 0.5±0.12 for patients with a score of 8 or
9 (P=0.01, unpublished data). This finding prompted us to
introduce the in vitro drug resistance score as an additional
parameter for risk assignment in the subsequent CoALL
06-97 trial. Given the low rate of accrual of 110 patients
per year this could not be done in a randomized fashion. 
Patients with a sensitive PVA profile were candidates for
therapy reduction irrespective of the assigned risk arm. In
contrast, therapy was intensified in patients with a resist-
ant PVA profile, but only in low-risk patients because a
further escalation of dose intensity did not seem feasible
in high-risk patients.
A moderate reduction in therapy was performed in a
substantial number of patients with a sensitive PVA pro-
file, with this number being three times greater than the
number of patients receiving treatment intensification.
Although treatment intensity was adjusted according to
the PVA score in the CoALL 06-97 study, patients with a
sensitive PVA profile nevertheless had a better outcome
than that of patients with an intermediate or resistant PVA
profile. Patients from the CoALL 06-97 study and those
from the predecessor CoALL 05-92 trial with a sensitive
PVA score (3 or 4) had a similar long-term pEFS, although
the former patients had received therapy reduction. The
reduced intensity regimen resulted in a significant decline
of the rate of infectious complications, which were more
than halved in the low-risk group and diminished by 36%
in the high-risk patients.26
A separate subgroup analysis of the CoALL 06-97 data
revealed that low-risk patients undergoing intensified
treatment according to the PVA score had an excellent out-
come, which was not very different from that of the low-
risk patients with sensitive or intermediate scores. The
small number of patients in the previous study did not,
however, allow for a test of equivalence.
With longer follow-up of the original CoALL 05-92
cohort it became apparent that the PVA score predicted
early rather than late relapses leading to a decrement of
the prognostic power of the score over time.16 This obser-
vation also holds true for the CoALL 06-97 study. The PVA
score was of significant prognostic value exclusively in
high-risk patients, who generally develop a relapse within
the first 2 years after completion of therapy. However,
since therapy was intensified only in low-risk patients
with a high PVA score, treating them as high-risk patients,
the prognostic impact of the PVA score in the low-risk
group may disappear. 
The prognostic impact of in vitro drug sensitivity testing
per se is restricted by the selection of drugs. Analysis of the
prognostic impact of sensitivity to the single drugs incor-
porated in the PVA score revealed that in vitro sensitivity
towards asparaginase alone was still an independent pre-
dictor of relapse in both risk groups, suggesting that cur-
rent therapy is not suitable for overcoming L-asparaginase
resistance. The observation that the asparaginase score
lost its predictive power when MRD was integrated in the
multivariate analysis might be due to a selection of identi-
cal patients by both methodologies but a stronger predic-
tive power of MRD. In vitro sensitivity towards pred-
nisolone was associated with a superior prognosis only in
a univariate analysis. A prognostic impact of in vitro sensi-
tivity to vincristine could not be found. This suggests that
the impact of resistance to these two drugs on outcome
was lost upon treatment adaption. Previous studies
showed that in vitro sensitivity to vincristine and pred-
nisolone had a significant impact, but the number of
patients included in these studies was substantially small-
er than that in the present CoALL study, which may also
account for the conflicting results.1-3,9
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It is becoming increasingly clear that immunological
control mechanisms play a pivotal role in the maintenance
of long-term remission. Blasts that remain unrecognized
by the immune system or hide in immunological niches
may give rise to relapse. These host-specific factors are not
adequately reflected by in vitro systems testing sensitivity
to drugs, but might well contribute to the treatment
response measured in vivo; MRD levels, in contrast, also
account for host pharmacokinetics, pharmacodynamics
and pharmacogenetics.
This comment is in line with data from a substantial
number of studies showing that MRD levels within the
first 4-5 weeks of treatment are highly predictive of the
outcome of children with ALL.5-7,17,18 In patients with B-
precursor ALL the NOPHO group observed a significant
correlation between MRD level at day 15 (i.e. after induc-
tion) and in vitro sensitivity to prednisolone, vincristine and
doxorubicin, drugs that were used in the induction thera-
py. In the CoALL 06-97 trial a correlation between in vitro
drug resistance and in vivo response to chemotherapy
could only be found in patients with T-ALL but not in
those with B-precursor ALL. The PVA score as determined
in the CoALL 05-92 and 06-97 trials comprises sensitivity
against prednisolone, vincristine and asparaginase, but the
last – not given in CoALL induction - was the only drug
which strongly correlated with MRD in T-ALL patients.
In summary, treatment reduction in the CoALL 97 trial
was feasible for patients with a sensitive in vitro drug test-
ing profile without introducing an increased risk of
relapse. Besides the immediate prevention of life-threaten-
ing infectious complications, this treatment reduction is
anticipated to have a long-term benefit of reducing late
adverse effects such as anthracycline-induced cardiotoxic-
ity. 
Surprisingly, no correlation was found between the in
vitro response to drugs and in vivo MRD levels in patients
with B-precursor ALL. Although in vitro drug testing is a
simple, up-front and low cost diagnostic tool, it has been
abandoned in favor of the more predictive, but somewhat
sophisticated, in vivo evaluation of MRD in the ongoing
CoALL trial which yields a clear cut and robust separation
of risk groups.
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